Identifying a nasal gene expression signature associated with hyperinflation and treatment response in severe COPD
Alen Faiz, Kai Imkamp, Erica van der Wiel, Ilse M Boudewijn, Gerard H Koppelman, Corry-Anke Brandsma, Huib A M Kerstjens, Wim Timens, Sebastiaan Vroegop, Henk R Pasma, Wim G Boersma, Pascal Wielders, Frank van den Elshout, Khaled Mansour, Katrina Steiling, Avrum Spira, Marc E Lenburg, Irene H Heijink, Dirkje S Postma, Maarten van den Berge, Alen Faiz, Kai Imkamp, Erica van der Wiel, Ilse M Boudewijn, Gerard H Koppelman, Corry-Anke Brandsma, Huib A M Kerstjens, Wim Timens, Sebastiaan Vroegop, Henk R Pasma, Wim G Boersma, Pascal Wielders, Frank van den Elshout, Khaled Mansour, Katrina Steiling, Avrum Spira, Marc E Lenburg, Irene H Heijink, Dirkje S Postma, Maarten van den Berge
Abstract
Hyperinflation contributes to dyspnea intensity in COPD. Little is known about the molecular mechanisms underlying hyperinflation and how inhaled corticosteroids (ICS) affect this important aspect of COPD pathophysiology. To investigate the effect of ICS/long-acting β2-agonist (LABA) treatment on both lung function measures of hyperinflation, and the nasal epithelial gene-expression profile in severe COPD. 117 patients were screened and 60 COPD patients entered a 1-month run-in period on low-dose ICS/LABA budesonide/formoterol (BUD/F) 200/6 one inhalation b.i.d. Patients were then randomly assigned to 3-month treatment with either a high dose BDP/F 100/6 two inhalations b.i.d. (n = 31) or BUD/F 200/6 two inhalations b.i.d. (n = 29). Lung function measurements and nasal epithelial gene-expression were assessed before and after 3-month treatment and validated in independent datasets. After 3-month ICS/LABA treatment, residual volume (RV)/total lung capacity (TLC)% predicted was reduced compared to baseline (p < 0.05). We identified a nasal gene-expression signature at screening that associated with higher RV/TLC% predicted values. This signature, decreased by ICS/LABA treatment was enriched for genes associated with increased p53 mediated apoptosis was replicated in bronchial biopsies of COPD patients. Finally, this signature was increased in COPD patients compared to controls in nasal, bronchial and small airways brushings. Short-term ICS/LABA treatment improves RV/TLC% predicted in severe COPD. Furthermore, it decreases the expression of genes involved in the signal transduction by the p53 class mediator, which is a replicable COPD gene expression signature in the upper and lower airways.Trial registration: ClinicalTrials.gov registration number NCT01351792 (registration date May 11, 2011), ClinicalTrials.gov registration number NCT00848406 (registration date February 20, 2009), ClinicalTrials.gov registration number NCT00158847 (registration date September 12, 2005).
Conflict of interest statement
IMB reports fees paid to the University from GlaxoSmithKline. GHK reports institutional grants from the Lung Foundation of the Netherlands, TEVA, GlaxoSmithKline, Ubbo Emmius Foundation, and TETRI Foundation. HAMK reports institutional grants from Novartis, Boehringer Ingelheim, and GlaxoSmithKline; speaking fees from Boehringer Ingelheim; consultant fees from AstraZeneca, Chiesi, GlaxoSmithKline, and Novartis; board membership with Chiesi, GlaxoSmithKline, and Novartis; and institutional patient fees from Fluidda. WT reports fees paid to the University from Pfizer, GlaxoSmithKline, Chiesi, Roche Diagnostics/Ventana, Biotest, Merck Sharp Dohme, Novartis, Lilly Oncology and a grant from the Dutch Asthma Fund. KS has a patent 9,677,138 issued for the Boston University, Annual royalties from UpToDate for co-authoring an UpToDate chaptor on Gene Expression, honoraria from Acdemic Research Coalition LLC for serving as expert faculty member and speaker at annual Respiratory Disease Young Investigators’ Forum, Grant from Lungevity Foundation. MEL reports stock from Metera Pharmaceuticals. DSP reports consultancy fees or research grants paid to the University from AstraZeneca, Chiesi, Genentec, GlaxoSmithKline, Roche. MvdB reports research grants paid to the University from Chiesi, GlaxoSmithKline and TEVA. AF, KI, EvdW, CAB, SV, HRP, WgB, PW, FvdE, KM, AS and IHH have no competing interests.
Figures
References
- Mannino DM, Kiriz VA. Changing the burden of COPD mortality. Int. J. Chron. Obstruct. Pulmon. Dis. 2006;1:219–233.
- Siafakas NM, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur. Respir. J. 1995;8:1398–1420. doi: 10.1183/09031936.95.08081398.
- O’Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2006;3:180–184. doi: 10.1513/pats.200508-093DO.
- MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005;2:258–266. doi: 10.1513/pats.200504-045SR.
- Yoshida T, Tuder RM. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol. Rev. 2007;87:1047–1082. doi: 10.1152/physrev.00048.2006.
- Agusti A, Soriano JB. Dynamic hyperinflation and pulmonary inflammation: A potentially relevant relationship? Eur. Respir. Rev. 2006;15:68–71. doi: 10.1183/09059180.00010003.
- Nadel JA, Takeyama K, Agustí C. Role of neutrophil elastase in hypersecretion in asthma. Eur. Respir. J. 1999;13:190–196. doi: 10.1034/j.1399-3003.1999.13a35.x.
- Celli BR, MacNee W, ATS/ERS Task Force Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur. Respir. J. 2004;23:932–946. doi: 10.1183/09031936.04.00014304.
- O’Donnell DE, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006;130:647–656. doi: 10.1378/chest.130.3.647.
- John M, Bosse S, Oltmanns U, Schumacher A, Witt C. Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respir. Med. 2005;99:1418–1424. doi: 10.1016/j.rmed.2005.03.034.
- Heijink IH, et al. Role of aberrant WNT signalling in the airway epithelial response to cigarette smoke in chronic obstructive pulmonary disease. Thorax. 2013;68:709–716. doi: 10.1136/thoraxjnl-2012-201667.
- Gower AC, Steiling K, Brothers JF, Lenburg ME, Spira A. Transcriptomic studies of the airway field of injury associated with smoking-related lung disease. Proc. Am. Thorac. Soc. 2011;8:173–179. doi: 10.1513/pats.201011-066MS.
- van den Berge M, et al. Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity. Thorax. 2014;69:14–23. doi: 10.1136/thoraxjnl-2012-202878.
- Steiling K, et al. A dynamic bronchial airway gene expression signature of chronic obstructive pulmonary disease and lung function impairment. Am. J. Respir. Crit. Care Med. 2013;187:933–942. doi: 10.1164/rccm.201208-1449OC.
- Vucic EA, et al. DNA methylation is globally disrupted and associated with expression changes in chronic obstructive pulmonary disease small airways. Am. J. Respir. Cell Mol. Biol. 2014;50:912–922. doi: 10.1165/rcmb.2013-0304OC.
- Cvejic A, et al. SMIM1 underlies the Vel blood group and influences red blood cell traits. Nat. Genet. 2013;45:542–545. doi: 10.1038/ng.2603.
Source: PubMed